Administration of AVP

Phase 3Small molecule

AAssistance Publique - Hôpitaux de Paris

Administration of AVP is one of 105 small molecule programs targeting Cognition. It is currently in Phase 3.

Indications

Total Trials

Active Trials

104

Competitors

Pipeline

Status by Indication[3][1]

Indication

CognitionActive, not recruiting

Multiple MyelomaNot yet recruiting

CarcinomaCompleted

HydrocortisoneRecruiting

CognitionPreclinical

Active, not recruiting

Multiple MyelomaPhase 2

Not yet recruiting

CarcinomaPreclinical

Completed

HydrocortisonePhase 3

Recruiting

Competition

Competitive Landscape

258 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Belamaf

GSK

Phase 3

39 2

Empliciti

Bristol-Myers Squibb

Phase 3

43 3

Fludara

Sanofi

Phase 3

47 4

TALVEY

Johnson & Johnson

Phase 3

22 5

Sarclisa

AAzienda U.S.L. 1 di Massa e Carrara

Phase 3

42 6

Biaxin

AbbVie

Phase 3

14 7

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

28 8

Azatiq

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

22 9

Vepesid

Elranatamab

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 2Not yet recruiting

Multiple Myeloma

NCT07348393

Clinical

Trials by Indication[1]

Cognition1 trial

Rapid Recognition of Corticosteroid Resistant or Sensitive Sepsis

Recruiting·AAssistance Publique - Hôpitaux de Paris·N/A·NCT04280497·1,800 enrolled

Carcinoma1 trial

Testicular Function After Iodine 131 Therapy in Papillary Carcinoma Patients

Completed·AAssistance Publique - Hôpitaux de Paris·N/A·NCT01150318·48 enrolled

Multiple Myeloma1 trial

A Phase 2, Single Arm Multicenter, Study Testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT07348393·70 enrolled

Hydrocortisone1 trial

HYdrocortisone and VAsopressin in Post-RESuscitation Syndrome

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT04591990·380 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Administration of AVP. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Administration of AVP compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Administration of AVP. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assistance Publique - Hôpitaux de Paris company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAssistance Publique - Hôpitaux de Paris

Administration of AVP

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Cognition1 trial

Carcinoma1 trial

Multiple Myeloma1 trial

Hydrocortisone1 trial

References

Drug Info

Quick Facts

Related News